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AbstrACt
Introduction Little is known about the applicability of 
mindfulness- based interventions in Spanish adults with 
overweight/obesity. The objective of the present study 
protocol is to describe the methods that will be used in a 
cluster randomised trial (CRT) that aims to evaluate the 
effectiveness of a mindfulness eating (ME) programme to 
reduce emotional eating (EE) in adults with overweight/
obesity in primary care (PC) settings.
Methods and analysis A CRT will be conducted with 
approximately 76 adults with overweight/obesity from 
four PC health centres (clusters) in the city of Zaragoza, 
Spain. Health centres matched to the average per capita 
income of the assigned population will be randomly 
allocated into two groups: ‘ME +treatment as usual (TAU)’ 
and ‘TAU alone’. The ME programme will be composed 
of seven sessions delivered by a clinical psychologist, 
and TAU will be offered by general practitioners. The 
primary outcome will be EE measured by the Dutch Eating 
Behaviour Questionnaire (DEBQ) at post test as primary 
endpoint. Other outcomes will be external and restrained 
eating (DEBQ), binge eating (Bulimic Investigatory Test 
Edinburgh), eating disorder (Eating Attitude Test), anxiety 
(General Anxiety Disorder-7), depression (Patient Health 
Questionnaire-9), mindful eating (Mindful Eating Scale), 
dispositional mindfulness (Five Facet Mindfulness 
Questionnaire) and self- compassion (Self- Compassion 
Scale). Anthropometric measures, vital signs and blood 
tests will be taken. A primary intention- to- treat analysis 
on EE will be conducted using linear mixed models. 
Supplementary analyses will include secondary outcomes 
and 1- year follow- up measures; adjusted models 
controlling for sex, weight status and levels of anxiety 
and depression; the complier average causal effect of 
treatment; and the clinical significance of improvements.
Ethics and dissemination Positive results of this 
study may have a significant impact on one of the most 
important current health- related problems. Approval 
was obtained from the Ethics Committee of the Regional 
Authority. The results will be submitted to peer- reviewed 
journals, and reports will be sent to participants.
trial registration number NCT03927534 (5/2019).
bACkground
According to WHO, overweight and obesity 
are disorders in which there is abnormal or 
excessive fat accumulation in adipose tissue 
that can be harmful to health.1 They are 
defined operationally as a body mass index 
(BMI)—weight in kilograms divided by the 
square height in metres (kg/m²)—from 25 
to 29.9 and ≥30 kg/m2, respectively. WHO 
estimated that, in 2014, 39% of adults world-
wide were overweight (approximately 38% 
of men and 40% of women), and 13% were 
obese (approximately 11% of men and 15% 
of women).2 In absolute terms, it is estimated 
that approximately 1 billion adults are over-
weight and that at least 300 million are obese 
throughout the world, with an increasing 
prevalence in most countries.3 Unhealthy diet 
and the lack of physical activity are important 
causes of obesity4 and also the most important 
non- communicable obesity- related diseases, 
such as cardiovascular disease, type 2 diabetes 
and certain types of cancer.5 6 They contribute 
strengths and limitations of this study
 ► This study is going to lead the first intervention 
based on mindful eating applied to overweight and 
obesity in the Spanish primary care (PC) context.
 ► It will open new perspectives about current recom-
mendations included in the clinical guidelines for the 
treatment of these conditions in Spanish PC settings.
 ► It will carry out a long- term follow- up using both bi-
ological and psychological assessments to analyse 
changes that the treatment may produce.
 ► The sample size used will be a main limitation, be-
cause it has been estimated based on foreign works 
due to the lack of previous studies in the Spanish 
context.
Protected by copyright.
 o
n
 February 5, 2020 at Universidad de Zaragoza. Biblioteca.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031327 on 21 November 2019. Downloaded from 
2 Morillo Sarto H, et al. BMJ Open 2019;9:e031327. doi:10.1136/bmjopen-2019-031327
Open access 
substantially to global morbidity, mortality and disability 
burden.7 Obesity has been associated with a higher prev-
alence of hypertension, dyslipidaemia, sedentary lifestyle, 
diabetes, subclinical organ injury and cardiovascular 
disease,8 depression,9 migraine10 and hypertension.11
Even in the Mediterranean region (in which Spain is 
located), traditionally associated with a healthy lifestyle, 
the evolution of eating habits has led to a progressive 
abandonment of the traditional pattern, for example, 
decrease in the consumption of fruits and vegetables 
and increase in the consumption of fast food, especially 
among the youngest age groups.12 These eating style 
changes have also been complemented by a physical 
activity decrease pattern and longer sedentary time.13 
In fact, Mediterranean countries currently express high 
obesity prevalence rates.14 15 The investigation of new ways 
to treat this problem in the primary care (PC) context is 
developing successfully, although incipiently, throughout 
virtual platforms that allow for the training and interac-
tion of different professionals.16 The most common users 
of the PC system are patients between 45 and 75 years, and 
precisely this age range presents a higher prevalence of 
overweight and obesity than other age groups in Spain.17 
Reducing the prevalence of obesity is not an easy task 
because a multiplicity of factors may be involved.18 In most 
cases, an individualised and multidisciplinary treatment 
is recommended because of the efficiency and resource 
complexities that such treatment may involve.19 20 Obesity 
treatment is a challenge to which societies have not yet 
adequately responded, and the prevalence of obesity has 
increased, leading to an encrusted problem.21
There are factors on which experts agree: diet and 
physical activity are fundamental pillars for the treatment 
of obesity to achieve a ‘negative’ energy balance.22 The 
fundamental objective in the initial treatment of over-
weight and obesity is to reduce body fat until it reaches 
a level that allows for an improvement in health and 
a reduction, as much as possible, in risk factors.23 To 
achieve long- term maintenance of weight loss, it is essen-
tial to modify and establish habits related to diet, eating 
patterns and physical activity.19 24 25 However, between 
25% and 30% of patients with obesity seeking treatment 
to reduce their weight suffer from a marked depression 
condition or other psychological disorders. Thus, physi-
cians or psychologists should routinely inquire about the 
mood, sleep, appetite, fun activities and eating patterns of 
patients with obesity. In fact, individuals with obesity with 
marked depression, anxiety or binge- eating problems 
may require pharmacological treatment and/or psycho-
therapy before trying to lose weight.26
Psychological treatments, mostly included in the cogni-
tive–behavioural therapy umbrella, have shown favour-
able, but not definitive, results for weight loss.27 However, 
not all the studies reviewed have showed such positive 
outcomes,28 29 and given the intense debate in this field, 
there is an evident need for more trials and long- term 
evaluations. Less encouraging in their long- term results 
are other psychological treatments employed, such as 
psychoanalysis or hypnosis.30 31 On the other hand, it has 
been established that between one and two- thirds of the 
people who follow restricted diets gain more weight than 
they lose.32 The degree to which restricted diets are coun-
terproductive has probably been underestimated due to 
several methodological problems, focusing on the results 
of successful weight loss instead of the long- term main-
tenance of weight loss. Moreover, studies do not provide 
consistent evidence that dietary restriction results in 
significant health improvements, regardless of possible 
weight change32; in fact, it is a significant contributor to 
binge eating.33 Nevertheless, changes in dietary habits do 
not necessarily have associated restrictions, since healthy 
changes may be made to food consumption without 
restriction, such as a healthy choice of food.34–36
At this point, a fundamental debate in the field has 
been the consideration or not of weight loss as a main 
outcome.37 Weight is a very simple measure that is not 
always directly related to the interaction that a person 
has with food, because there may be other factors to take 
into account, such as endocrine disorders or drug treat-
ments. However, it has been observed that the consump-
tion of certain problematic foods and eating behaviours, 
such as binge eating and eating linked to the satisfaction 
of emotional needs rather than the satisfaction of phys-
ical hunger, are related to the presence of obesity.38 In 
fact, our relationship with food is an important issue. 
Recently, a line of study interested in promoting the 
conscious choice of food, developing awareness of the 
differences between physical hunger and psychological 
hunger, noticing the satiety signs and eating healthily as 
a response to all those signals, has been developed.39 40 
Within this current stream of the literature, the ‘mindful 
eating’ (ME) movement emphasises being aware of the 
present moment when one is eating, paying attention 
to the effect that food has on the senses and taking 
into account the physical and emotional sensations in 
response to the eating process.37 41
The first ME study42 showed that, through a 7- session 
group programme, it was possible to reduce the number 
of binge- eating episodes, as well as depressive symptom-
atology. The meditative practice related to eating was 
the best predictor regarding the improvement in eating 
control. Later, although a pilot study found no effects 
on weight change,43 it was observed that ME produces 
improvements in depressive symptoms, expectations of 
results, food- related self- efficacy and cognitive control 
with respect to eating behaviours in patients suffering 
from diabetes.39 44 More robust studies have concluded 
that dispositional mental awareness plays an important 
role in eating behaviours, supporting the use of ME 
feeding techniques in diabetes self- management inter-
ventions.45 It has recently been stated that ME seems to be 
an effective approach to weight and glycaemic control in 
people with diabetes, and thus, promoting mindfulness 
could be one of several behavioural tools to support key 
self- care aspects to regulate glycosylated haemoglobin.46 
ME has also shown efficacy in binge- eating disorders47 
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and could contribute to weight loss and a reduction in 
sweets consumption and fasting glucose levels,36 although 
only moderate effects have been found when specifically 
trying to reduce weight in the long term.48
It has been said that ME appears to be effective in 
addressing emotional eating (EE), binge eating and 
eating in response to external cues, with the poten-
tial of improving problematic eating behaviours and 
controlling food intake.48 However, evidence of ME 
training on weight is mixed and additional research to 
determine comparative and long- term effects is needed.49 
In recent years, EE—that is overeating in response 
to negative emotions50—has been seen as a potential 
explanatory factor of the complexity of overweight and 
obesity.51 It has been observed that: (1) EE interacts with 
loss of control eating, increasing disordered eating atti-
tudes, BMI and adiposity52; (2) EE is implicated in the 
use of compensatory behaviours to regulate weight50; 
and that (3) decreases in EE are associated with weight 
loss success in overweight adults.53 It has been suggested 
that ME approaches might have a positive influence 
as adjuvant therapies for weight management and for 
the development of a more conscious eating style with 
healthier eating behaviours.54 55 This could be achieved 
because mindfulness- based programmes which usually 
incorporates training in dispositional mindfulness and 
self- compassionate attitudes improve emotion regula-
tion processes,56 which in turn are inversely related to 
EE,51 suggesting the treatment of overweight and obesity 
should focus on calorie- restricted diets and on emotion 
regulation skills. However, to the best of our knowledge, 
no studies have attempted to improve these eating vari-
ables in patients suffering from overweight or obesity 
using ME interventions in the Spanish PC context.
objectives
The main aim of this study will be to evaluate an ME 
psychological intervention plus treatment as usual (‘ME 
+TAU’) to promote a healthy change in relations with 
food by reducing EE in patients with overweight or obesity 
in PC settings, compared with a control group that will 
receive medical treatment as usual (‘TAU alone’). The 
secondary aims will be to assess the possible differences 
between groups in external, restrained, binge and ME as 
well as eating disorder risk, anxiety, depression, disposi-
tional mindfulness and self- compassion. Finally, we will 
also explore the possible differences in anthropometric, 
vital sign and blood test measures to determine the scope 
of the intervention on these physical parameters.
The principal hypothesis is that ‘ME +TAU’ will be more 
effective than ‘TAU alone’ in reducing EE in patients 
with overweight or obesity in PC settings. The secondary 
hypothesis is that ‘ME +TAU’ will function better than 
‘TAU alone’ to improve the levels of external, restrained, 
binge and ME, eating disorder risk, anxiety, depression, 
dispositional mindfulness and self- compassion, as well as 
the anthropometric, vital sign and blood tests physical 
parameters.
trial design
This study is a multicentre, two- armed, parallel, cluster 
randomised trial (CRT) with PC health centres as clusters, 
with pretreatment, post- treatment and 1- year follow- up 
measures, and an equal cluster allocation rate between 
groups as well as equal cluster size. PC centres (ie, clus-
ters) in the city of Zaragoza, Spain, will be randomly 
assigned to two different conditions, with one psycholog-
ical intervention group (‘ME +TAU’) or one usual treat-
ment group (‘TAU alone’) managed by their general 
practitioner (GP), to test the superiority of the ‘ME 
+TAU’ provision compared with the ‘TAU alone’ provi-
sion, considering outcomes at the individual participant 
level. A CRT design will be used because the intervention 
will be performed in PC settings and persons within the 
same PC health centre may respond more similarly to 
the intervention than persons drawn from different PC 
health centres—they could have more characteristics in 
common owing to the fact of sharing the same environ-
ment and deliverer of intervention treatment (GP).57 
For ethical reasons, those PC health centres allocated to 
‘TAU alone’ will also be offered the ME programme after 
finishing the trial at 1- year follow- up.
MEthods
This protocol was designed in accordance with the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials 2013 statement.58 The timeline of the study is 
presented in table 1.
Participants, study setting and eligibility criteria
Participants will be chosen from the four PC health centres 
of Las Fuentes Norte, Parque Goya, La Almozara and La Jota 
in the city of Zaragoza (Spain). The city of Zaragoza has a 
population of 663 023 inhabitants, with approximately an 
average age of 44 years, a percentage of women of 52%, 
an average per capita income of €11 800, a percentage of 
emigrants of 14% and a dependency rate of 53%.59 Each 
of the four PC health centres has an assigned population 
of between 10 000 and 24 000 patients whose average 
age is between 41 and 46 years, a percentage of women 
between 51% and 53%, an average per capita income 
between €9000 and €12 000, a percentage of emigrants 
between 6% and 17% and a dependency rate of between 
41% and 58%, and thus can be considered representa-
tive of the PC health centres of Zaragoza according to the 
previously described variables. Patients will be selected by 
GPs working in the PC centres (with one GP for each PC 
health centre, which will function as a cluster). When the 
GPs observe potential participants who meets the eligi-
bility criteria, they will be informed about the general 
characteristics of the study, providing them with the 
opportunity to participate. The inclusion and exclusion 
criteria of the patients are specified in table 2.
Within the general framework of promoting healthy 
and active lifestyles in the community, participants are 
required to have two of the following three risk factors in 
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Table 1 Schedule of enrolment, interventions and assessments
Study period
Timepoint
Enrolment Allocation Intervention
12- month 
follow- up
April
2019
May
2019
June
2019
July
2019
August 
2019
September 
2019
June/August
2020
Enrolment
  Eligibility form X
  Informed consent X
  Allocation X
Interventions
  ME+TAU C1(1)   
  ME+TAU C1(2)   
  ME+TAU C2(1)   
  ME+TAU C2(2)   
  TAU alone C3   
  TAU alone C4   
Assessments
  Sociodemographic X
  DEBQ X X X X X
  BITE X X X X X
  EAT-26 X X X X X
  FFMQ X X X X X
  SCS X X X X X
  MES X X X X X
  GAD-7 X X X
  PHQ-9 X X X
  Weight (kg) X X X
  Waist perimeter (cm) X X X
  Vital signs (DBP, SBP) X X X
  Cholesterol (HDL, LDL) X X X
  Glucose X X X
  HbA1c X X X
  ALT X X X
ALT, alanine aminotransferase; BITE, Bulimic Investigatory Test Edinburgh; C, cluster (subgroup in brackets); DBP, diastolic 
blood pressure; DEBQ, Dutch Food Behaviour Questionnaire; EAT-26, Eating Attitude Test; FFMQ, Five Facet Mindfulness 
Questionnaire;GAD-7, General Anxiety Disorder; HbA1c, glycosylated haemoglobin;HDL, high density lipoprotein; LDL, low density 
lipoprotein; MES, Mindful Eating Scale; ME+TAU, Mindful eating;PHQ-9, Patient Health Questionnaire; SBP, systolic blood pressure; 
SCS, Self- Compassion Scale; TAU, treatment as usual.
order to be included in the study: (1) sedentary lifestyle, 
(2) poor diet or (3) binge episodes. GPs will evaluate 
the suitability of patients for the trial in terms of their 
age and overweight/obesity condition, ability to under-
stand Spanish and willingness to participate in the study. 
A psychologist assessor will assess the level of physical 
activity, using the International Physical Activity Ques-
tionnaire—a sedentary lifestyle will be established in case 
of a low level of physical activity60; a possible poor diet, 
using the Diet Quality Index- International—a poor diet 
will be considered when obtaining a score <5061; and the 
presence of binge episodes, using the Bulimic Investiga-
tory Test Edinburgh (BITE)—with a cut- off point of two 
binge episodes in a week.47
Exclusion criteria were derived from the typical criteria 
used to rule out patients in this type of study, including 
serious mental illness, acute- phase depression, schizo-
phrenia or psychotic disorders, drug abuse or depen-
dence and medical conditions that make it difficult to 
participate in the intervention.62–64 These exclusion 
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Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Age between 45 and 75 years
 ► Overweight or obesity condition (individuals with BMI ≥25)
 ► Two of these three risks: sedentary lifestyle, poor diet or 
binge episodes
 ► Ability to understand oral and written Spanish
 ► Willingness to participate in the study and sign informed 
consent
 ► Any diagnosis of a disease that may affect the central 
nervous system (brain condition, traumatic brain injury, 
dementia, etc.)
 ► Other psychiatric diagnoses or acute psychiatric illness 
(eg, substance dependence or abuse, schizophrenia or 
other psychotic disorders), except for anxiety or personality 
disorders
 ► Presence of delusional ideas or hallucinations whether 
consistent or not with mood
 ► Suicide risk
BMI, body mass index.
criteria will add proper functioning to the intervention 
groups and also patient safety, avoiding possible exac-
erbations of psychosis, mania or suicidal ideation.65–67 
Anxiety or personality disorders will not be excluded 
so as not to bias the selected sample, because they are 
particularly related to eating disorders.68 69 All in all, an 
adequate monitoring through the study will be carried 
out regarding the safety of all patients (described next). If 
patients are interested in participating, they will be asked 
to sign a written informed consent form. Patients who do 
not accept participation will be treated in their PC centres 
as usual due to ethical reasons.
Patient and public involvement
The research question was based on one of the most 
principal problems that the PC population suffers from. 
Patients and GPs require more tools to face the existing 
high prevalence of overweight and obesity, which leads 
to more risk and high costs for society.70 71 Taking this 
into account, we started with an 8- session uncontrolled 
open- label pilot study offered to the public in general, 
with the main aim of adjusting an ME programme to the 
PC population.
We recruited 10 patients from the Arrabal PC health 
centre in the city of Zaragoza who were willing to partici-
pate (8 women and 2 men, with an age range of between 
45 and 65 years). After the last session of this early iter-
ation, we inquired specifically about the content of the 
programme and the results they could have experienced 
during these 8 weeks, the appropriateness of the length 
of the intervention and about homework management. 
We did not quantitatively assess the potential changes 
of this pilot presentation because we were more inter-
ested in how they experienced the programme, as well as 
possible implementation issues. We specifically asked for 
the following aspects: ‘How do you feel about the content 
and results of the programme?’, ‘Has the programme 
been long enough?’ and ‘Did you follow the weekly home 
task?’ The most common responses pointed out that the 
content of the programme was helpful and had changed 
their level of awareness of unhealthy eating patterns, but 
also that the programme had too many sessions, and 
that the home tasks were too difficult to be carried out 
during the programme. Due to the good participation 
and feedback obtained, and considering the difficul-
ties reported, we decided to continue working on this 
research line involving patients and GPs. Following the 
comments of the pilot participants, we adjusted the orig-
inal programme length down to seven sessions, and also 
lightened the homework load.
The individual results of the present study will be 
shared by email with the corresponding participants who 
express their desire to know the results. The resulting 
publications will also be disseminated to participants, 
and a free lecture of a summarised report, once the study 
has finished, will be offered. In addition, participants 
will answer a questionnaire that includes open questions 
regarding the professionals involved, the programme and 
their own experience.
sample size
The sample size estimation has been based on the main 
comparison, which contemplates the possible differences 
between the ‘ME +TAU’ and ‘TAU alone’ groups of 
patients. Based on previous research,72 we assume that ‘ME 
+TAU’ would be able to present high effects compared 
with ‘TAU alone’ on EE at post test. To operationalise 
this, we consider a standardised difference between arms 
on the referred main outcome of 0.80.72 To detect this 
difference between the groups, assuming a common SD, a 
5% significance level and a statistical power of 80% using 
a 1:1 ratio, we need 25 subjects in each group. However, 
these numbers correspond to the sample size needed 
under individual randomisation, which is the absolute 
upper bound for cluster size—clusters are randomised 
and thus we need to allow for the correlation between 
the EE outcomes of participants from the same cluster.73 
To determine the minimum number of clusters needed, 
we used the formula ‘n * ICC’, where n is the sample size 
for each arm under individual randomisation and ICC 
is the intracluster correlation coefficient that quantifies 
the amount of within- cluster correlation for the outcome 
of interest, assuming a typical fairly value in CRTs of 
ICC=0.03,74 with a result of approximately one cluster in 
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Figure 1 Restricted randomisation applied to primary care 
(PC) health centres. Figure represents the matching process: 
the maximally homogeneous PC health centres pairs in terms 
of the predefined average per capita income of the assigned 
population (higher average per capita income pair and lower 
average per capita income pair) will be divided randomly 
between the ‘mindful eating (ME) + treatment as usual (TAU)’ 
(intervention) and only ‘TAU’ (control) arms. The number of 
points reflects the cluster size. C, cluster.
each arm. Because the number of clusters in the trial is 
limited by the number of PC settings available to imple-
ment the ME programme, we increased the number of 
clusters to one more than the minimum, supposing that 
the cluster size would be at most ‘n/1’. Thus, we fixed 
the number of clusters per arm to 2 in order to deter-
mine the required cluster size.75 In order to maintain the 
same absolute difference and significance level described 
above to achieve 80% power with 2 clusters in each arm, 
we needed a cluster size of 16 participants. In addition, 
by fixing the cluster size at 16 participants in the same 
conditions, we obtained the need of 2 clusters per arm, 
equating to a total sample size of 64 subjects under the 
condition of equal cluster sizes. Finally, we inflated the 
numbers to reach a total sample size of 76 patients (38 
per arm), considering a drop- out rate of approximately 
20% at 1- year follow- up.76 This can be considered an effi-
cient design based on the rule that cluster size should 
not exceed the number estimated in each arm under 
individual randomisation.73 This number also enlarges 
the sample size under individual randomisation in a 
measure that includes the design effect ‘DEFF=1 + (m – 
1) * ICC’—where m is the average number of patients per 
cluster—with a value of DEFF=1.45, and thus demanding 
an increase with regard to individual randomisation of 
around 45%.57
recruitment
Participants will be identified and recruited in PC settings 
by involving the GPs of patients who fulfil the study 
criteria. The GPs will complete referral forms, indicating 
that the patients meet the criteria and will provide a 
brochure and an information sheet to present the study. 
The GPs will send the referrals and the patients’ signed 
written consent forms by mail to a local researcher. Some 
patients may prefer to postpone their decision to partici-
pate in the study, in which case they will be provided with 
information about how to contact the research team (by 
phone, email or leaving their information on the group’s 
website).
An assessor- researcher, who is not part of the study 
team, will contact the participants to agree on the estab-
lished evaluation times and will clarify any points, ensure 
that the participants have read the information about 
the study, and ensure they have understood the two 
experimental conditions. The assessor will then finally 
determine their inclusion in the study after considering 
the inclusion and exclusion criteria described above, 
and before contacting an independent researcher to 
implement the randomisation sequence to the clusters. 
Recruitment will be performed consecutively until the 
final sample size is reached. The assessor will collect the 
baseline data, including the primary outcome. GPs will 
adhere to the study protocol before the randomisation of 
clusters, and they will be blinded to the allocation group 
of clusters together with the assessor- researcher. Possible 
migrations of participants out of clusters will be especially 
taken into account so as not to lose post- treatment and 
follow- up measures.
randomisation, allocation and masking of study groups
The identification and inclusion of participants will take 
place before the randomisation of clusters, ensuring 
allocation concealment to cluster guardians (who are 
the corresponding GPs), assessors and patients during 
recruitment.77 78 Restricted randomisation will be applied 
to balance clusters, creating comparable arms in terms 
of the number of clusters but also in the average per 
capita income of the assigned population to each PC 
health centre.79 The rationale of this is that this variable 
has been inversely related to the presence of overweight 
and obesity,80 81 and also to possible limitations in gaining 
benefits after mindfulness- based programmes.82 The 
maximally homogeneous cluster pairs in the average per 
capita income at the level of PC health centres will be 
matched and randomly divided between the intervention 
and control arms, as shown in figure 1. As a result of this 
matching process, we will obtain a number of strata that 
is half the total number of clusters to be allocated, which 
is considered the minimum number of clusters to safely 
achieve balance.83 This matching procedure is partic-
ularly useful when there are few clusters in the study,84 
and it provides face validity regarding balance between 
allocation arms.85 No other cluster or individual- level 
imbalances for important covariates related to the main 
outcome are expected between arms.
An independent assistant not involved in the study 
will be in charge of performing the cluster randomi-
sation by using a computer programme to generate an 
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unpredictable random allocation sequence. This assistant 
will be unaware of the characteristics of the study and will 
inform the data manager of a code that corresponds to 
the type of treatment to be added to the baseline data. 
The meaning of this code will be unknown by the person 
in charge of randomisation and by the data manager—
it will be known only to the data monitoring committee 
(DMC) and will be kept under a password- protected data-
base system. The DMC will receive the baseline data from 
the data manager and will be in charge of implementing 
the random sequence.
Participants will agree to their inclusion before finding 
out the treatment to which they will be allocated. As we 
have previously explained, the baseline assessor will be 
blind to the type of treatment that will be administered to 
clusters and patients. This assessor will be different from 
the person responsible for collecting the post- test and 
follow- up measurements, who will be a blinded external 
assistant specifically advised not to ask for the study 
aims and the allocation of clusters/patients. GPs will be 
blinded to the intervention arm to which each patient 
is allocated since their intervention should be based 
only on usual practice, and they will also be advised not 
to ask for that information. The person responsible for 
performing the data analysis will be blinded to the type of 
intervention in the main outcome analysis, receiving the 
database without any data that permits this identification. 
Any doubt regarding the data will be resolved in contact 
with the data manager, and the other researchers will be 
blinded while analysis and data interpretation processes 
are taking place. However, due to the characteristics of 
the intervention, participants will be able to know what 
kind of intervention they are receiving; thus, this will be a 
single blind study—although both ‘ME +TAU’ and ‘TAU 
alone’ groups will be treated one way or another. A verifi-
cation of successful blinding at all stages referred will be 
performed by the DMC.
data management
A researcher psychologist will perform the data handling 
and monitoring. All study information will be confined 
in secure drawers with limited access. Electronic data 
files will be password protected. Participant codes and 
personal information will be stored in a separate password- 
protected file. Data will be stored for 5 years after the end 
of the study. Only the researchers directly involved in the 
study and led by the principal investigator will have access 
to the final dataset. Paper- based data entry will be double 
checked, and possible out- of- range values will be specifi-
cally revised. In case data are actually correct, they will be 
analysed altogether by boxplot graphical representations 
to see whether the previously described values constitute 
extreme outliers. If extreme outliers appear, a sensitivity 
analysis after removing them will be performed to ensure 
robustness of results. The study results will be presented 
via peer- review publications and congresses. In addition, 
the study participants will receive a summarised report on 
request, and the funders and involved clinicians will also 
receive an anonymised report.
Interventions
All participants, regardless of the treatment arm in which 
they have been assigned, will receive the TAU at the PC 
level. According to the pragmatic nature of the present 
study, ad hoc adherence optimisation procedures will 
not be used, as not to interfere with diverse routine prac-
tices. In fact, patients will be free to decide whether they 
will discontinue intervention on request. If participants 
decide to be part of any other medical or psychological 
treatment focused on changing their relation with the 
food or weight reduction, the contact person of the study 
should be informed to exclude those participants when 
developing the corresponding data analyses. The rest of 
the treatments will be allowed.
 Treatment as usual
TAU in PC is any kind of treatment administered by the 
GP to the patient with overweight or obesity. According 
to nutritional status, overweight or obesity, as well as the 
presence of comorbidity, different actions can comprise 
the treatment offered at the PC level. For individuals 
presenting with overweight (BMI 25–29.9 kg/m2) or 
obesity (≥30 kg/m2) but with no comorbidities, PC 
teams organise care plans adjusted to the characteris-
tics of patients to enable them to achieve a normal BMI 
range (BMI 18.5–24.9 kg/m2). In cases of suicide risk, 
severe social dysfunction or worsening of symptoms, it 
is recommended that patients are referred to mental 
health facilities.86 In Spain, GPs spend a minimum of 4 
years completing their medical specialty. The GPs who 
will be participating in the present study have more than 
20 years of clinical experience treating patients with over-
weight or obesity, and they will have undergone specific 
training focused on endocrinology and internal medicine 
for a better understanding of obesity and its implications 
and comorbidities such as diabetes and hypertension.
 Mindful eating
The ME group will be composed of 7 weekly group 
sessions with a minimum duration of 2 hours, mixing 
theoretical content with practices. Sessions will always be 
the same day of the week, except for bank holidays or 
eventualities, and will be conducted by a clinical psychol-
ogist. This psychologist has been specially trained in ME 
programmes, for example, Mindfulness- Based Eating 
Awareness87 and Mindful Eating Conscious Living,88 and 
he is also a board member of The Center for Mindful 
Eating (TCME).89 The TCME is a non- profit interna-
tional organisation that provides resources for educating 
professionals in the field of ME. This clinical psycholo-
gist has also run several ME groups over the past 5 years 
and he is a coauthor of the manual on which the present 
programme was based.90 Group sizes will range between 
8 and 12 participants in four different subgroups of treat-
ment. At the end of each session, participants will receive 
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Table 3 Summary of the mindful eating sessions and content
Session Content Practices Home task
Session 1
Mindful eating introduction
 ► Brief introduction
 ► Importance of the present moment
 ► Attention and motivation
 ► Breathing practice
 ► Raisin practice
 ► Minimeditation
 ► Breathing practice
 ► Decreasing the eating rhythm
Session 2
Mindful eating and 
compassion
 ► What to do with your body and your mind 
while meditating
 ► What emotional eating is and how to 
distinguish it from physical eating
 ► Using compassion to achieve change
 ► Body scan practice
 ► Healing self- touch
 ► Minimeditation
 ► Body scan
Session 3
Integrating consciousness
 ► Body signals
 ► Hunger and satiety
 ► Mindful eating practice
 ► Integrating consciousness 
practice
 ► Self- acceptance
 ► Breathing practice
 ► Becoming aware of hunger 
and satiety signals
Session 4
Satiety and appetite values
 ► How to structure mindfulness practice 
(formal and informal)
 ► Eating psychoeducation
 ► Compassionate body scan
 ► Personal value practice
 ► Chocolate practice
 ► Minimeditation
 ► Stopping in the middle of 
the meal
 ► Body scan
Session 5
Conscious choice and 
forgiveness
 ► Compassionate coping
 ► Knowing when to stop eating
 ► Potluck preparing
 ► Conscious choice
 ► Full stomach practice
 ► Forgiveness meditation
 ► Conscious movements
 ► Becoming aware of the 
continuous feeling while 
eating until satiety
Session 6
New balance consciousness
 ► My plate
 ► Potlucking
 ► Nutrition and emotional eating triggers 
(chain)
 ► Mindful walking practice
 ► Emotional self- regulation
 ► Potluck practice
 ► Emotional eating chain
 ► Mindful walking
 ► Becoming aware of our 
feelings and their adjustment
Session 7
Wisdom and pursuing the 
path
 ► Keeping up with the knowledge
 ► Facing yourself after relapses
 ►  Breaking the chain
 ►  Wisdom meditation
 ►  Our inner critical voice
–
theoretical content and homework activities to be prac-
tised during the week. The programme is summarised in 
table 3 and described as follows:
 ► Session 1: this session is aimed at motivating home 
practice and is complemented by an introduction to 
ME. Observation is an attitude that will be developed 
during this session, allowing patients to connect with 
their emotions, thoughts and body sensations, moment 
by moment, to be aware of possible unhealthy eating 
patterns. The awareness of automatised patterns can 
give patients the chance to change behaviour, making 
decisions more connected with necessities. The ME 
efficacy mechanisms are explained.
 ► Session 2: the objective of this session is to be aware, at 
any moment, of one’s hunger level, observing eating 
patterns and their possible relation with the emotions 
that are felt at the same time. This session works by 
identifying EE triggers and knowing how compassion 
and the inner critical voice are related to the food.
 ► Session 3: the objective is to recognise the differences 
between real hunger signals and other body sensa-
tions generated by the environment that trigger the 
desire to eat. Training at the body consciousness level 
helps one find the point of balance that allows for 
eating and enjoying, paying attention to eating, feel-
ings, body sensations, emotions and thoughts.
 ► Session 4: This session aims to work with the 
corporal sensations that food produces. When the 
physical sensations are of discomfort, swelling or 
heaviness, this indicates that the food intake was 
excessive. When the sensation is related to satiety, 
this is a good moment to stop eating. The satiety 
signal is identified through mindfulness (chocolate 
practice).
 ► Session 5: it address the fullness sensation as some-
thing different from not being hungry and the ‘EE’ 
concept. It encourages us to accept all we experiment, 
managing the inner critical voice. The practice of 
conscious movements to become aware of the body 
and bring full attention to the present moment is a 
guide in decision- making.
 ► Session 6: this session emphasises the relationship 
between the knowledge of feeding and nutrition and 
conscious and balanced decision- making. It works 
with emotional triggers through the chain practice 
and also integrates the potluck practice. Foods that 
trigger greater EE are shared and discussed in the 
group.
 ► Session 7: this session is focused on binge episodes 
and how we can manage EE in the future by substi-
tuting the inner critical voice with a compassionate 
voice. The way we are aware of our thoughts, emotions 
and decisions is what allows us to break the chain of 
EE and start a new relationship with food, managing 
and making decisions about emotions and food in a 
wiser way.
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outcomes
Patients will be assessed at baseline, after treatment and 
at 1- year follow- up to test whether the improvements 
achieved during therapy are maintained in the long term. 
Several variables will be assessed to compare the ‘ME 
+TAU’ and ‘TAU alone’ groups to evaluate the effects of 
the ME programme. EE styles, which will compose the 
main outcome, have a direct relation with overweight 
and obesity.51 These eating styles are related to how much 
you eat and even more to how you eat. The Dutch Eating 
Behaviour Questionnaire (DEBQ) is a good evaluator 
of this construct (EE is a subscale of this questionnaire) 
and has been rated ‘up to the mark’, that is, appropriate, 
by the Dutch Committee on Test and Testing and by the 
European Federation of Psychologists Association.91
The secondary outcomes will be other eating patterns 
that could be modified as a result of the application of 
the programme, such as external and restrained eating, 
also measured by the DEBQ (both are also subscales 
of this questionnaire); binge eating, measured by the 
BITE92; and eating disorder risk, measured by the Eating 
Attitude Test (EAT).93 Other secondary outcomes will 
be emotional states, which affect the way we eat. To eval-
uate this, the General Anxiety Disorder (GAD-7), which 
is one of the most frequent screening scales in PC, will 
be used to assess anxiety.94 The GAD-7 is often used in 
combination with the Patient Health Questionnaire 
(PHQ-9) to measure depressive symptoms, which will 
also be included.95–100 Physiological variables will also be 
important to evaluate whether changes in eating style and 
emotional state have consequences for the general health 
condition in the long term. For this purpose, anthropo-
metric and vital signs will be assessed—including weight, 
abdominal diameter, diastolic blood pressure (DBP) and 
systolic blood pressure (SBP)—as well as blood tests, all of 
which are described next.
To relate the awareness of the present moment and the 
way in which compassionate and critical attitudes towards 
the self can be managed as possible emotion regulation 
strategies,56 101 the evaluation of the dispositional mind-
fulness and self- compassion levels will be pursued as 
mechanistic variables of the programme through appli-
cation of the widely used Five Facet Mindfulness Ques-
tionnaire (FFMQ), the Mindful Eating Scale (MES) and 
the Self- Compassion Scale (SCS). Mindfulness is a way 
of self- regulating attention to focus it on the present 
moment experience with an attitude of curiosity, open-
ness and acceptance of bodily sensations, thoughts and 
emotions.102 Deficits in dispositional mindfulness have 
been reported in patients suffering from eating disor-
ders and obesity.103 104 It has also been observed that the 
non- judgemental awareness of physical and emotional 
sensations, specifically associated with eating, correlates 
inversely with the severity of eating disorders105 and 
increases healthy food choices.106 Finally, self- compassion 
has received much attention in assisting individuals with 
eating behaviours and weight regulation.107 It is a kind 
approach towards oneself, with a mindful awareness and 
understanding of one’s experiences as part of shared 
reality that all people go through during personally 
challenging or difficult times.108 It has been observed 
that receiving a self- compassionate induction to cope 
after the experience of breaking the diet enables further 
regulation to occur,109 and that self- compassion could 
be a determinant for weight regulation and losing 
weight.110 111 Overall, the combination between mindful-
ness and self- compassion appears to be complementary, 
creating better health- related outcomes for both eating 
behaviours and obesity.55 All the study measurements, 
together with the sociodemographic data taken at base-
line, are summarised in table 4.
 Sociodemographics
The following sociodemographic information will be 
collected at baseline: age, sex, nationality, marital status 
(single, married, separated/divorced or widowed), work 
activity (student, worker, sick leave, unemployment, 
housewife, disability or retired), study level (no studies, 
primary, secondary or university) and the PC health 
centre of provenance in the city of Zaragoza, Spain (Las 
Fuentes Norte, Parque Goya, La Almozara or La Jota).
 Main outcome
The DEBQ was designed to measure eating styles that 
may attenuate or contribute to the development of 
overweight and obesity.112 It comprises three scales that 
measure emotional, external and restrained eating. 
The EE pattern corresponds to the tendency towards 
overeating in response to negative emotions113 and will 
be considered the main outcome of this study (both 
external and restrained subscales will be included as 
secondary outcomes even though they are presented 
here). Emotional and external eating are correlated with 
BMI. The restraint factor has shown relationships with 
other scales, such as the EAT-26 and the Restrain Scale, 
which measure eating disorders and restrained eating, 
respectively. The Spanish version112 of the DEBQ114 has 
33 items, 13 of which refer to the EE scale (eg, ‘Desire to 
eat when irritated’) and 10 of which refer to the external 
(eg, ‘Eating when you feel lonely’) and restrictive (eg, 
‘Difficult to resist delicious food’) scales. The items can 
be rated on a five- point Likert- type scale, with a score 
of 1 indicating ‘never’ and 5 indicating ‘very often’. In 
a non- clinical sample of normal weight, overweight, 
and obese participants, Cronbach’s alpha coefficients 
presented values between 0.96 and 0.97 for the DEBQ- EE 
subscale, between 0.79 and 0.84 for the DEBQ- external 
eating subscale and between 0.92 and 0.94 for the DEBQ- 
restrained eating subscale.33
 Secondary outcomes
We will administer the BITE92 in its Spanish version.115 
This questionnaire is used to measure the presence of 
bulimic symptoms in non- clinical samples and has two 
subscales measuring symptoms (eg, ‘Desire to eat when 
irritated’; with 30 items in a ‘yes’/‘no’ dichotomous scale; 
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Table 4 Study outcomes
Variables Assessment area Level of measurement Time to assessment
Sociodemographic Age, sex, nationality, marital status, work activity, 
study level and PC health centre
Varies depending on the 
distribution of data
Baseline
DEBQ Eating style: emotional, external and restrained 
eating
Treated as interval Baseline, post treatment and 
1- year follow- up
BITE Binge eating: symptoms, severity and frequency of 
bingeing
Treated as interval Baseline, post treatment and 
1- year follow- up
EAT Eating disorder: dieting, bulimia and food 
preoccupation, and oral control
Treated as interval Baseline, post treatment and 
1- year follow- up
GAD-7 General anxiety symptoms Treated as interval Baseline and 1- year follow- up
PHQ-9 Depression symptomatology Treated as interval Baseline and 1- year follow- up
FFMQ Mindfulness: observing, describing, acting with 
awareness, non- judging and non- reactivity
Treated as interval Baseline, post treatment and 
1- year follow- up
MES Mindful eating: acceptance, awareness, non- 
reactivity, acting with awareness, routine and 
unstructured eating
Treated as interval Baseline, post treatment and 
1- year follow- up
SCS Self- compassion: self- kindness, self- judgement, 
common humanity, isolation, mindfulness, and 
overidentification
Treated as interval Baseline, post treatment and 
1- year follow- up
Anthropometrics Weight, height, waist circumference and abdominal 
diameter
Treated as ratio Baseline and 1- year follow- up
Blood test Cholesterol total, LDL, HDL, triglycerides, ALT, 
glucose and glycated haemoglobin
Treated as ratio Baseline and 1- year follow- up
Vital signs Systolic and diastolic blood pressure Treated as ratio Baseline and 1- year follow- up
Attendance Compliance with the programme Treated as interval Post treatment
ALT, alanine aminotransferase; BITE, Bulimic Investigatory Test Edinburgh;DEBQ, Dutch Eating Behaviour Questionnaire; EAT, Eating 
Attitude Test; FFMQ, Five Facet Mindfulness Questionnaire; GAD-7, General Anxiety Disorder; MES, Mindful Eating Scale;PC, primary 
care; PHQ-9, Patient Health Questionnaire; SCS, Self- Compassion Scale.
range=0‒30) and severity (eg, ‘Do you do any of the 
following to help you lose weight?’; with 6- dimensional 
items addressing bulimic behaviours; range=0‒39), with 
a total of 33 items. In addition to normative values for 
total and subscale scores in clinical and nonclinical 
samples,116 another measure has been derived to report 
the frequency of bingeing (item no. 27, ‘If you do binge, 
how often is this?’; this item will be mainly framed in 
the last month so as not to overlap pretest and post- test 
measures, with the following type of response: ‘2–3 times 
a day’=6; ‘Once a day’=5; ‘2–3 times a week’=4; ‘once a 
week’=3; ‘once a month’=2; ‘almost never’=1). The BITE 
has shown an internal consistency value of α=0.96 for the 
symptoms and of α=0.62 for the severity subscales.117
To assess any other eating disorder, we will use the 
EAT-26,93 in its Spanish version.118 This questionnaire 
has the following three subscales: dieting (eg, ‘Am terri-
fied about being overweight’), bulimia and food preoc-
cupation (eg, ‘Find myself preoccupied with food’) and 
oral control (eg, ‘Avoid eating when I am hungry’). The 
EAT-26 is an abbreviated version of the original EAT-40, 
with an excellent correlation between them (r=0.98). In 
the EAT-26, each item is answered on a 6- point Likert- type 
scale (‘always’=3, ‘usually’=2, ‘often’=1, ‘sometimes’=0 
‘rarely’=0 and ‘never’=0), and if the score is 20 or higher, 
the patient should seek professional advice. The EAT-26 
has an elevated reliability (α=0.80).
The GAD-7 is one of the most frequently used diag-
nostic self- report scales for screening, diagnosis and 
anxiety disorder severity assessment,119 defined as an 
excessive anxiety and worry (apprehensive expectation) 
related to a number of events or activities associated with 
experiencing difficulties to control that worry.120 Items 
(eg, ‘Not being able to stop or control worrying’) are 
rated on a 4- point Likert- type scale (between 0 = ‘not 
at all’ and 3 = ‘nearly every day’). The GAD-7 inquires 
about events occurring over the last 2 weeks to know 
how often the patient has been bothered by them, and 
it has shown a sensitivity of 89% and a specificity of 82% 
when discriminating patients suffering from generalised 
anxiety disorder. The Spanish version of the GAD-7 has 
shown appropriate psychometric characteristics.121
We will use the PHQ-9122 to assess depressive symp-
tomatology. This scale is one of the most widely used 
questionnaires to assess the intensity of depression in 
pharmacological and psychological studies.123 124 It is 
useful to monitor the changes experienced by patients 
over time and presents a sensitivity value of 88% and a 
specificity of 88% to detect major depression. Through 
items such as ‘Little interest or pleasure in doing things’ 
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and using a Likert- type scale between 0 (‘not at all’) and 
3 (‘nearly every day’), the PHQ-9 reflects the experience 
of participants during the last 2 weeks. The Spanish vali-
dated version, which has shown adequate psychometrics, 
will be used.86
 Process measures
The FFMQ- short form125 is a 24- item questionnaire that 
measures 5 aspects of trait mindfulness, and there is 
a Spanish version based on it with appropriate psycho-
metrics.126 The five facets of the FFMQ are observing 
(eg, ‘I pay attention to physical experiences, such as the 
wind in my hair or sun on my face’; four items, α=0.65), 
describing (eg, ‘I am good at finding words to describe 
my feelings’; five items, α=0.79), acting with awareness 
(eg, ‘It seems I am running on automatic without much 
awareness of what I am doing’—item reversed; five items, 
α=0.80), non- judging towards inner experience (eg, ‘I 
make judgements about whether my thoughts are good 
or bad’—item reversed; five items, α=0.73) and non- 
reacting of inner experience (eg, ‘When I have distressing 
thoughts or images, I do not let myself get carried away 
by them’; five items, α=0.68). The participants indicate, 
on a 5- point Likert- type scale, the degree to which each 
item is generally true for them, ranging from 1 (‘never or 
very rarely true’) to 5 (‘very often or always true’). Higher 
scores indicate greater levels of mindfulness.
It has been observed that mindful awareness towards 
eating may minimise automatic and impulsive reactions, 
thereby fostering self- regulation.127 We will measure ME 
through the MES questionnaire.128 The MES question-
naire has 28 items, including the following 6 factors: 
acceptance (α=0.89; assessed through items such as ‘I 
criticize myself for the way I eat’), awareness (α=0.82; 
for example, ‘It is easy for me to concentrate on what I 
am eating’), non- reactivity (α=0.77; for example, ‘I can 
tolerate being hungry for a while’), acting with awareness 
(α=0.81; for example, ‘I eat something without really 
being aware of it’), routine (α=0.75; for example, ‘I have a 
routine for what I eat’) and unstructured eating (α=0.60; 
for example, ‘I multi- task while eating’. Items can be rated 
on a 4- point Likert- type scale, with 1 indicating ‘never’ 
and 4 indicating ‘very often’. The MES Spanish validated 
version has shown adequate psychometric features.128
The SCS129 is the most used self- report instrument to 
measure self- compassion. It is divided into six subscales: 
self- kindness (eg, ‘I am kind to myself when I am expe-
riencing suffering’); self- judgement (eg, ‘When I see 
aspects of myself that I do not like, I get down on myself’); 
common humanity (eg, ‘I try to see my failings as part 
of the human condition’); isolation (eg, ‘When I fail at 
something that is important to me, I tend to feel alone in 
my failure’); mindfulness (eg, ‘When something upsets 
me, I try to keep my emotions in balance’); and overiden-
tification (eg, ‘When something upsets me, I get carried 
away with my feelings’). The items can be rated on a five- 
point Likert- type scale, with 1 indicating ‘almost never’ 
and 5f indicating ‘almost always’. After reversing the 
negatively formulated items, a total score can be calcu-
lated, which may range from 24 to 120, with higher scores 
indicating greater self- compassion.129 The SCS total has 
shown good internal reliability (Cronbach’s α=0.92), as 
did the six subscales (ranging from α=0.75 to α=0.81.129 
The Spanish validated version of the SCS has demon-
strated good psychometric properties.130
 Physical parameters
Weight and body measurements will be quantified, with 
weight in kilograms, and height, waist circumference 
and abdominal perimeter in centimetres (cm); weight 
without any anthropometric measures is not an accu-
rate assessment of the physical changes associated with 
a healthy food relation. The evaluations will be made the 
same day and just before the psychometric assessments, 
using a measuring tape and the same digital scales. 
Blood tests will evaluate the levels of total cholesterol 
(HDL and LDL), triglycerides, alanine aminotransferase, 
glucose and glycated haemoglobin. The blood test will be 
performed in the morning (between 08:00 and 09:00, and 
all participants should have fasted for 8 hours prior to the 
test. Vital signs such as DBP and SBP will also be assessed. 
To evaluate vital signs, we will use a vascular screening 
system (version VaSera VS-1500).
 Other measures
In addition, the number of ME programme group 
sessions attended, as well as the number of visits to the 
corresponding GP in both groups, will be recorded. Video 
recordings will not be taken in order not to interfere with 
the natural way in which exercises are held.
harms
Thus far, there is no described evidence in the literature 
regarding any side effect as a result of specific ME prac-
tice, although participation in meditation programmes 
in general might exacerbate negative experiences to 
the same extent as psychotherapy.131 Any adverse event 
observed by the GPs or psychologist in charge of the 
groups or referred from patients during the sessions or 
along the whole programme will be communicated to the 
trial manager (the leader of the research group, who is a 
psychiatrist and will be able to refer the patient directly to 
mental health services should this be necessary), and also 
to an independent GP and an independent psychologist 
with broad experience in the clinical field of mindfulness 
and eating disorders; they will act together to form the 
DMC. If the unintended effects are related to the treat-
ment, the DMC will be committed to informing the corre-
sponding PC physician and providing the individualised 
treatment to each case scenario in PC settings or derived 
to mental health services by their PC physician or the 
trial manager if required. Then, the DMC and the corre-
sponding PC physician will decide whether to discon-
tinue or modify the allocated intervention depending on 
the nature and severity of the side effects. The DMC will 
audit trial conduct at least three times throughout the 
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study (after baseline, post treatment and follow- up assess-
ments, as well as at the request of any of the members of 
the research group), in coordination with the psycholo-
gist responsible for data handling and the psychologist 
in charge of the groups—but independently of the other 
parts. To ensure that the procedures are being correctly 
implemented and that the trial works adequately, audits 
will revise aspects such as the level of attendance in group 
sessions and TAU, adverse events emerged through the 
study and possible extreme cases that might require 
specific attention in any of the variables assessed.
Analysis strategy
The reporting of the results will follow the Consolidated 
Standards of Reporting Trials recommendations.132 133 
Sociodemographic and clinical data will be described at 
baseline by means of frequencies and percentages, for 
categorical variables, or by means and SDs, for contin-
uous variables. Treatment conditions will be compared 
at baseline by visual inspection to ensure the success of 
randomisation, as recommended.134
 Main analysis
The effectiveness of ‘ME +TAU’ compared with ‘TAU 
alone’ will be estimated at post test, based on the EE main 
outcome, which will be considered a continuous variable 
at the individual level. Multilevel mixed- effect regression 
models—including time as an independent variable and 
subjects and PC health centre (cluster) as random- effect 
variables—will be developed by means of a repeated- 
measures (RM) design on an intention- to- treat basis, 
using the restricted maximum likelihood method. This 
method is considered robust in the case of small and/or 
unbalanced sample sizes.135 Non- standardised and unad-
justed slopes as well as 95% CI will be calculated. To study 
the specific trajectories of each group throughout the trial 
and determine whether the differences between groups 
are consistent over time, the ‘group × time’ interaction 
will be calculated as a supportive analysis (ie, the 1- year 
follow- up time point will be considered as a secondary 
analysis). Cohen’s d effect sizes (ESs) from raw scores 
will be estimated at each time point using the combined 
SD at baseline.136 ESs are considered small when d≤0.2; 
medium when d=0.5 and large when d≥0.8.137
 Secondary analyses
A recent study observed that multiple imputation is not 
necessary before computing RM mixed effects model anal-
ysis irrespective of the type of missing data,138 and other 
studies have suggested there are no gains in imputing 
outcomes in randomised trials.139 140 Thus, imputed 
scores will not be calculated to estimate sensibility analyses 
regarding any statistics. Nevertheless, supportive analysis 
of the EE main outcome at 1- year follow- up, as well as 
models of EE at post test and at follow- up with the interac-
tion of sex, weight status and the baseline levels of anxiety 
and depression as possible covariates, will be considered. 
Relationships have been observed between EE and sex 
(females present higher EE), weight status (the more the 
EE the higher the weight status) and emotional disorders 
derived from anxiety and depression (higher levels of 
anxiety and depression are associated with greater levels 
of EE),50 141 142 and thus these variables will be included 
in the adjusted models.143 The effectiveness of the ‘ME 
+TAU’ compared with the ‘TAU alone’ group with regard 
to the secondary outcomes, process variables and physical 
parameters will be calculated following the same analyt-
ical strategy used for the main unadjusted analysis. In 
addition, secondary outcomes will be also analysed using 
adjusted models controlling for sex, weight status, anxiety 
and depression. ESs of all the adjusted models will be esti-
mated from adjusted average marginal effects (AMEs), 
using the actual observed values for the variables whose 
values are not otherwise fixed.144
Further exploratory analyses of the EE primary outcome 
will be developed to estimate the complier average causal 
effect of treatment (CACE) in order to assess the poten-
tially unbiased effect of fully participating.145 Compliers 
will be only observed among those randomised to receive 
the ME programme (ie, individuals assigned to the 
control group will not have access to the ME treatment), 
and will be defined as those patients who attend at least 
≥50% of the ME sessions.146 A new variable will be created 
to identify whether each patient randomised to the ME 
group finally complied or not. Both within- cluster and 
between- cluster baseline covariates of compliers and non- 
compliers (intervention group) will be compared, and 
the CACE estimation will be calculated using the robust 
maximum likelihood expectation- maximisation algo-
rithm for a multilevel mixture model, considering both 
clustering and non- compliance.147
The clinical significance of improvements between 
groups will be explored by calculating the absolute risk 
reduction and the number needed to treat (and their 
95% CI). We will use two criteria for improvement: (1) 
changing to a less severe cluster in the EE main outcome148 
compared with the one the patient was allocated to at 
baseline, and (2) calculating the clinical significance of 
improvements by establishing both the cut- off point and 
reliable change index on the EE main outcome using the 
Jacobson and Truax method.149
 Level of significance
An alpha level of 0.05 will be established using a two- tailed 
test. The probability value relative to the sole primary 
model, as well as the probability values of secondary anal-
yses proposed, will not be adjusted on the basis of number 
of tests done, although they will be interpreted with due 
caution. No interim analyses will be carried out.
dIsCussIon
The present study proposes the evaluation of a leading 
and novel intervention based on ME in the field of 
overweight and obesity in the context of Spanish PC 
settings. The main interest of this study is to evaluate the 
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effectiveness of this treatment in changing the relation-
ship with food in patients suffering from overweight or 
obesity. The study addresses overweight and obesity from 
the point of view of the change in intake styles, specifi-
cally one of these, the emotional style of eating, which 
in turn has been linked to overweight and obesity condi-
tions.50 51 53 This study may be able to generate knowledge 
to expand the content included in the clinical guide-
lines for the treatment of these conditions in Spanish PC 
settings and throughout the healthcare system. To date, 
the implementation of these clinical guidelines has been 
shown to be improvable.150 There is a lack of knowledge 
in this particular field due to the novelty of mindfulness 
and self- compassion interventions in PC settings. One of 
the most important goals here is to generate processes to 
facilitate new effective programmes to control the high 
prevalence of overweight and obesity in PC. Mindfulness- 
based programmes seem to present certain effectiveness 
for treating obesity‐related eating behaviours, such as EE, 
external eating and binge eating, with also possible bene-
ficial effects in weight reduction,151–153 as well as depres-
sive symptoms154 and well- being.155
No particular difficulties are expected regarding the 
recruitment of PC health centres and patients with over-
weight/obesity or their participation and monitoring 
throughout the study.156–158 CRTs involve randomisation 
of groups of individuals to intervention or control groups, 
and their use is growing because they fit well with the func-
tioning of healthcare systems when introducing new forms 
of treatment. However, CRTs are particularly limited owing 
to the loss of follow- up from individuals and even more 
importantly from entire clusters when using restricted 
randomisation methods such as matching, which could 
suppose a break in the pairs of randomised clusters. To avoid 
this limitation, possible missing data will be minimised by a 
careful trial management of the PC professionals involved 
as cluster guardians and by attempting to follow- up all study 
participants.77 139 The long follow- up period could turn out 
to be an added difficulty when trying to evaluate all the 
participants at 1 year after the intervention—no outcome 
data will be collected for participants who do not complete 
follow- up. Nevertheless, with the assistance of the cluster 
guardians, efforts will be made to maintain low drop- out 
rates—ideally in the range of 20%—to reduce this possible 
limitation. We will also be cautious regarding ‘breaking the 
matching’ when determining the possible impact of base-
line covariates on the intervention effect, because it might 
increase type I error.159
Possible subsequent difficulties might be those derived 
from the fact that the sample size has been estimated 
based on foreign studies,72 because there have previously 
been no similar publications in the Spanish context. 
Another limitation is that the intervention will be located 
only in the city of Zaragoza (located in the north- east 
of Spain), without having the possibility to expand the 
study area. In this respect, the low number of PC health 
centres playing the role of clusters is likely to underesti-
mate standard errors, something that might lead to type 
I error increases, even using analyses that are prepared 
to account for clustering. Thus, we will have to be aware 
of whether observed standard errors tend to exaggerate 
the significance of results.147 Nevertheless, because we 
will model non- compliance and clustering in the CACE 
analysis, we will be able to reduce variance inflation due 
to the interaction between the two.
On the other hand, the measurement of different types 
of outcomes, using self- report instruments and anthro-
pometric and vital signs measures, as well as blood tests, 
will be a strength of the present study, thus overcoming 
possible response biases. Furthermore, the exclusion 
criteria established, although may favour group func-
tioning and patient safety, might also limit the range of 
potential affective symptoms and EE, which is likely to 
have implications for results. Finally, the fact that the 
instructor- led ME intervention is conducted in a group 
setting creates a particular context that could poten-
tially introduce significant biases related to attention and 
support that are not present in the same way in other 
forms of treatment delivery, such as individual face- to- 
face treatments or online psychotherapies.
Ethical aspects
Written informed consent will be obtained from the 
participants before they are aware of the group to which 
they are allocated. Patients will be informed with a 
detailed overview of the aims and characteristics of the 
study and the intervention arms, and also that all partici-
pants will be free to withdraw from the study at any time, 
before they provide their consent. As mentioned above, 
patients in the TAU arm will be allowed to partake in the 
psychological intervention programme at the end of the 
study for ethical reasons—they will be informed of this 
possibility after the 1- year follow- up measure to avoid the 
intrusion of possible expectations that might affect the 
development of the programme, level of participation or 
outcomes.
The study has been developed according to national 
and international standards, for example, Declaration 
of Helsinki, Tokyo Convention and the corresponding 
later amendments. The data will be treated anonymously 
and will only be used for purposes related to the study. 
The limits to fully guarantee confidentiality and privacy 
of the participants included in the study will rely on Fair 
Information Practice Principles (FIPPS)160—that is, open-
ness and transparency, purpose specification, collection 
limitation and data minimisation, use limitation, indi-
vidual participation and control, data quality and integ-
rity, security safeguards and controls, accountability and 
oversight—and will be in accordance with the ethical 
standards laid out in the EU General Data Protection 
Regulation regime as well as the Spanish Organic Law 
on Protection of Personal Data and Guarantee of Digital 
Rights, ensuring that the responsibility for protecting data 
privacy rests primarily on the data holders. If the necessity 
of fulfilling the objectives of the CRT creates a scenario 
that could lead to a break in the total compliance with 
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confidentiality, the FIPPS principles in accordance with 
the ethical standards referred above will ensure a frame-
work of privacy, autonomy and respect for the participants 
that will minimise the breach of the confidence and in 
turn the possibility of error due to low quality of data.161 
In cases of adverse events or unintended effects, the DMC 
will be responsible for ensuring anonymity.
The research team will only have access to the numer-
ical data of the results of the previously established tests 
derived from blood samples. Blood samples will be 
handled on a regular basis from the PC consultations and 
according to the regulation of the Spanish Royal Decree 
1277/2003. This study protocol has been approved by 
the Research Ethics Committee of the regional authority 
(CEICA Aragon, Spain registry number PI19/086). Any 
important modification of the protocol will be immedi-
ately communicated to this committee by both letter and 
email. Publication authorship of the final trial report will 
be based on making substantial contributions according 
to published scholarly work in medical journals.162
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